Published in TB and Outbreaks Week, September 13th, 1999
The vaccine is proven to protect against Neisseria meningitidis serogroup C meningococci, the principal cause of severe meningitis. University of Oxford researchers Martin C.J. Maiden and Brian G. Spratt welcome its imminent introduction.
They nevertheless warn that introduction of the vaccine could provide an ecological niche for other, highly virulent meningococci against which the vaccine offers no protection.
"The introduction of any vaccine that targets only a fraction of the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.